Jointly sponsored by the University of Cincinnati and Princeton CME
Target Audience
This activity is designed for managed markets physicians and pharmacists.
Learning Objectives
After completing this activity, participants should be able to:
- Summarize the prevalence and clinical and economic burden of ADHD in children and adults
- Describe the importance of consistent ADHD management to improve outcomes and avoid comorbidities
- Outline current data regarding the benefits and limitations of traditional, new, and emerging pharmacotherapies for ADHD management
- Apply the evidence to assist in implementation of effective strategies for the screening, diagnosis, and management of ADHD
Credit Eligibility
To be eligible for documentation of credit, all participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit. Those who mail or fax back their successfully completed post-test and evaluation form will receive documentation of credit by mail within 6 weeks.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.
Release date: June 14, 2007; Expiration date: July 31, 2008
Estimated time to complete: 1 hour
There is no fee associated with this activity.
CME Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Cincinnati and Princeton CME. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CPE Accreditation
Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 hour credit (0.1 CEU) of continuing pharmacy education (ACPE #452-999-07-012-H01).
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Continuing Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.
Grant Support
This activity is supported by an educational grant from Shire Pharmaceuticals, Inc.
Participating Faculty
Faculty
Julie A. Dopheide, PharmD, BCPP
Associate Professor of Clinical Pharmacy,
Psychiatry, and the Behavioral Sciences
University of Southern California
Schools of Pharmacy and Medicine
Los Angeles, California
Charnelda L. Gray, PharmD, BCPS
Assistant Manager
Clinical Pharmacy – Drug Utilization
Kaiser Permanente
Atlanta, Georgia
Jeffrey H. Newcorn, MD
Associate Professor
Psychiatry and Pediatrics
Director
Child and Adolescent Psychiatry
Mount Sinai School of Medicine
New York City, New York
Independent Clinical Reviewer
Steven W. Evans, PhD
Alvin V. Baird Jr. Centennial Chair of Psychology
Director, Alvin V. Baird Attention & Learning Disabilities Center
James Madison University
Harrisonburg, Virginia
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of the University of Cincinnati and Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Cincinnati and Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty reported the following:
Dr. Dopheide: Consultant (scientific)—Forest Laboratories, Ortho- McNeil, Inc; Speaker’s bureau (scientific)—Takeda Pharmaceuticals North America, Inc
Dr. Evans: Grant support (funds paid to James Madison University)—Eli Lilly and Company, Ortho-McNeil, Inc
Dr. Newcorn: Research (primary investigator)—Eli Lilly and Company, Ortho-McNeil, Inc; Research (funds paid to Mount Sinai Medical Center)—Novartis, Shire Pharmaceuticals, Inc; Consultant (scientific)— Cephalon, Cortex, Eli Lilly and Company, Lupin Limited, Novartis, Ortho-McNeil, Inc, Shire Pharmaceuticals, Inc; Consultant (promotional)— Novartis; Speaker’s bureau (scientific)—Eli Lilly and Company, Ortho-McNeil, Inc, Shire Pharmaceuticals, Inc; Speaker’s bureau (scientific and promotional)—Novartis
Dr. Gray disclosed no relevant financial relationships with any commercial interests.
Planning committee Kay Weigand, University of Cincinnati; Randy Robbin and John Savage, Princeton CME; and Erin Phelps and Rosemary Hodgson, Princeton Media Associates have disclosed no relevant financial relationships with any commercial interests.
The University of Cincinnati and Princeton CME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentations.
The faculty has disclosed the following discussion of off-label/unapproved uses of drugs or devices: modafinil, guanfacine, clonidine, venlafaxine, and bupropion in the treatment of ADHD.
Some of the clinical studies discussed in this activity may have been funded by manufacturers of drugs or devices.
